Advertisement

Topics

Collaboration to Identify NHL Patients with EZH2 Mutations for Epizyme's Phase 2 Trial

08:00 EDT 2 Aug 2017 | PharmPro

US Oncology Research and Epizyme establish collaboration to identify non-Hodgkin lymphoma patients with EZH2 mutations.
Contributed Author: 
Globe Newswire

Original Article: Collaboration to Identify NHL Patients with EZH2 Mutations for Epizyme's Phase 2 Trial

NEXT ARTICLE

More From BioPortfolio on "Collaboration to Identify NHL Patients with EZH2 Mutations for Epizyme's Phase 2 Trial"

Quick Search
Advertisement
 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Hodgkin lymphoma
Hodgkin Lymphoma is a  disorder caused by malignant proliferation of lymphocytes, which contain characteristic mirror-image nuclei (Reed-Sternburg cells). The resulting lymphadenopathy can be limited to a single lymph node region (Stage 1) or spread...